IXICO PLC · LSE:IXI

IXICO — FY2021 Earnings Presentation

19 slides from IXICO's earnings presentation, Dec 7, 2021

  1. Slide 1: FY21 Results

    Slide 1: FY21 Results

    FY21 Results 7th December 2021 Giulio Cerroni Grant Nash CEO CFO

  2. Slide 2: Nonregulated Disclaimer

    Slide 2: Nonregulated Disclaimer

    Nonregulated Disclaimer This presentation is incomplete without reference to, and should be viewed solely in conjunction with, the oral briefing which accompanies it. The information in this presentation is subject to updating, revision and amendment. The information in this presentation, which incl

  3. Slide 3: Delivering on our Purpose

    Slide 3: Delivering on our Purpose

    Npt aco Delivering on our Purpose

  4. Slide 4: IXICO: A company invested in a meaningful purpose

    Slide 4: IXICO: A company invested in a meaningful purpose

    IXICO: A company invested in a meaningful purpose To advance medicine and human health by turning medical imaging data (brain scans) into clinically meaningful information. We enable our pharmaceutical clients to gain valuable new insights to accelerate the development of new medicine in neuroscienc

  5. Slide 5: Impact of Aduhelm: First disease modifying drug for AD

    Slide 5: Impact of Aduhelm: First disease modifying drug for AD

    Impact of Aduhelm: First disease modifying drug for AD Jun-21 FDA approved Aduhelm for clinical 2021 FDA breakthrough therapy designations use in AD in AD • Expensive • Clinical benefit uncertain • Known side effects • Requirement for further studies & post-market surveillance • 3 ‘breakthrough ther

  6. Slide 6: IXICO: A company building valuable partnerships

    Slide 6: IXICO: A company building valuable partnerships

    IXICO: A company building valuable partnerships Ray and Dagmar Dolby Family Fund IXICO-GAP webcast can be found at the following link: https://www.brrmedia.co.uk/broadcasts/61aa006a504d020773e7e796/ixico-ixico-and-gap-interview/ Confidential and Proprietary Information

  7. Slide 7: FY21 Financials

    Slide 7: FY21 Financials

    Npt aco FY21 Financials

  8. Slide 8: Revenues broadly in line with prior year deliver strong Gross profit and EBITDA margins

    Slide 8: Revenues broadly in line with prior year deliver strong Gross profit and EBITDA margins

    Revenues broadly in line with prior year deliver strong Gross profit and EBITDA margins 9.5 9.2 1.7 67 66 1.3 7.6 65 56 59 0.5 5.4 45 4.1 3.1 -0.6 -1.4 -2.1 2016 2017 2018 2019 2020 2021 2016 2017 2018 2019 2020 2021 2016 2017 2018 2019 2020 2021 ▪ Stable revenues despite COVID-19 ▪ Gross margins su

  9. Slide 9: Order book impacted by short term challenges but better positioned for long term growth

    Slide 9: Order book impacted by short term challenges but better positioned for long term growth

    Order book impacted by short term challenges but better positioned for long term growth 16 projects; 14 clients; 21.7 9 new clients 19.3 18.8 9.2 15.9 12.7 13.8 21.7 9.9 7.5 18.8 2016 2017 2018 2019 2020 2021 30-Sep-20 Revenues Client trial Trial wins 30-Sep-21 descopes and fx ▪ Order book growth tr

  10. Slide 10: Order book diversified across trial phase and client numbers.

    Slide 10: Order book diversified across trial phase and client numbers.

    Order book diversified across trial phase and client numbers. 0.6 1.2 0.5 0.7 0.2 1.5 0.1 2.7 4.1 0.5 1.2 0.5 1.0 0.5 0.7 0.6 0.9 0.7 0.5 0.6 9.3 0.7 2.2 0.7 17.4 5.6 3.5 17.0 0.4 9.9 0.6 5.3 3.9 0.6 11.0 11.1 4.0 1.8 12.4 8.0 1.3 7.6 1.0 2.9 0.5 1.2 0.5 6.2 0.8 4.9 1.0 0.7 1.5 2.2 2.3 2.2 2.5 2.0 1

  11. Slide 11: Balance sheet oriented to support investment whilst growing

    Slide 11: Balance sheet oriented to support investment whilst growing

    Balance sheet oriented to support investment whilst growing 2.2 11.2 7.9 7.9 7.3 6.7 9.1 7.9 7.3 1.2 3.1 3.9 2.4 0.6 2.7 0.0 0.0 0.1 2016 2017 2018 2019 2020 2021 2016 2017 2018 2019 2020 2021 2016 2017 2018 2019 2020 2021 ▪ Technology investment of >£2.0m ▪ Investments in technology, scale and ▪ Ne

  12. Slide 12: TrialTracker: investing for future growth

    Slide 12: TrialTracker: investing for future growth

    TrialTracker: investing for future growth • Next generation TrialTracker platform • Microsoft Azure cloud infrastructure Clinical interpretation: standardised expert • Partnership with radiological reads Microsoft • Scale, resilience & security and efficiency • Supports deployment of new AI Data dri

  13. Slide 13: Shareholder value creation

    Slide 13: Shareholder value creation

    Shareholder value creation 13

  14. Slide 14: Share price: impacted by short-term client trial failures and doesn't reflect business traction

    Slide 14: Share price: impacted by short-term client trial failures and doesn't reflect business traction

    Share price: impacted by short-term client trial failures and doesn’t reflect business traction and market opportunity Descope of large PIII HD trials (£7.1m) Termination of client EV = 5*Revenues trial (£3.3m) 2nd large (£10.5m) PIII HD trial won Large (£9.1m) PIII HD trial won New CEO £5.5m Raise

  15. Slide 15: Strengthened market position: 5 years of organic growth

    Slide 15: Strengthened market position: 5 years of organic growth

    Strengthened market position: 5 years of organic growth Focus on Accelerate Target early Innovate Enhance delivering scale penetration phase to grow AI process organic growth and operational of clinical trials into later clinical automation through excellence market in select phases & advanced data

  16. Slide 16: Growth strategy; increased focus on point 5

    Slide 16: Growth strategy; increased focus on point 5

    Growth strategy; increased focus on point 5 Focus on Accelerate Target early Innovate Enhance delivering scale penetration phase to grow AI process organic growth and operational of clinical trials into later clinical automation through excellence market in select phases & data analytics selective t

  17. Slide 17: Appendix

    Slide 17: Appendix

    Npt aco Appendix

  18. Slide 18: Leadership Team: Focussed on Growth

    Slide 18: Leadership Team: Focussed on Growth

    Leadership Team: Focussed on Growth Delivery Grant Nash Romina Oxborough (Apr ‘19) (Sep ‘21) Chief Financial Officer SVP Operations Innovation Client focused Giulio Cerroni (Feb ‘17) Chief Executive Officer Robin Wolz Chris Hamilton (Mar ‘14) (Dec ‘21) Chief Scientific Officer SVP Commercial 18

  19. Slide 19: What we do today: Imaging in neuroscience clinical trials

    Slide 19: What we do today: Imaging in neuroscience clinical trials

    What we do today: Imaging in neuroscience clinical trials $1.6Bn imaging CRO clinical trials market* Focused on neurological (CNS) conditions with high unmet clinical need Business Model: “End to end” Solution; Regulatory-compliant operating model with global reach. Proposition: Advanced AI driven i

Source: Internet Archive copy of ixico.com

More decks from IXICO PLC

All 11 IXICO decks